CL2016002348A1 - Agonistas del receptor muscarínico - Google Patents

Agonistas del receptor muscarínico

Info

Publication number
CL2016002348A1
CL2016002348A1 CL2016002348A CL2016002348A CL2016002348A1 CL 2016002348 A1 CL2016002348 A1 CL 2016002348A1 CL 2016002348 A CL2016002348 A CL 2016002348A CL 2016002348 A CL2016002348 A CL 2016002348A CL 2016002348 A1 CL2016002348 A1 CL 2016002348A1
Authority
CL
Chile
Prior art keywords
compounds
receptor agonists
muscarinic receptor
agonists
muscarinic
Prior art date
Application number
CL2016002348A
Other languages
English (en)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Mark Pickworth
Benjamin Gerald Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CL2016002348A1 publication Critical patent/CL2016002348A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

<p>LA PRESENTE INVENCIÓN SE RELACIONA CON COMPUESTOS QUE SON AGONISTAS DEL RECEPTOR MUSCARÍNICO M1 Y QUE SON ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR MUSCARÍNICO M1. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS Y LOS USOS TERAPÉUTICOS DE LOS COMPUESTOS. LOS COMPUESTOS DERIVADOS DE PIPERIDINA ESPIROCONDENSADA, AGONISTAS DEL RECEPTOR MUSCARÍNICO M1; COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y USO EN EL TRATAMIENTO DE UN TRASTORNO COGNITIVO O PSICÓTICO, DONDE M, P, Q, W, Z, Y, X1 X2, R1, R2, R3 Y R4 SON TAL COMO SE DEFINIERON EN LA PRESENTE.</p>
CL2016002348A 2014-03-19 2016-09-16 Agonistas del receptor muscarínico CL2016002348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201404922A GB201404922D0 (en) 2014-03-19 2014-03-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CL2016002348A1 true CL2016002348A1 (es) 2017-07-07

Family

ID=50635044

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002348A CL2016002348A1 (es) 2014-03-19 2016-09-16 Agonistas del receptor muscarínico

Country Status (24)

Country Link
US (4) US10030035B2 (es)
EP (1) EP3119396B1 (es)
JP (3) JP6498691B2 (es)
KR (1) KR102368901B1 (es)
CN (2) CN106659719B (es)
AP (1) AP2016009445A0 (es)
AU (3) AU2015233140B2 (es)
BR (1) BR112016021590B1 (es)
CA (1) CA2942187C (es)
CL (1) CL2016002348A1 (es)
DK (1) DK3119396T3 (es)
EA (1) EA031245B1 (es)
ES (1) ES2872378T3 (es)
GB (1) GB201404922D0 (es)
HK (1) HK1231382A1 (es)
IL (1) IL247854B (es)
MX (2) MX2016012103A (es)
MY (1) MY193728A (es)
PH (1) PH12016501791B1 (es)
RU (1) RU2678835C2 (es)
SA (1) SA516371862B1 (es)
SG (1) SG11201607458QA (es)
UA (1) UA120928C2 (es)
WO (1) WO2015140559A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032479A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
JP2007522160A (ja) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
RU2007124373A (ru) * 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
AR057965A1 (es) 2005-12-05 2007-12-26 Incyte Corp Compuestos de lactama y metodos de uso de los mismos
CN101374519A (zh) * 2005-12-22 2009-02-25 弗特克斯药品有限公司 毒蕈碱性受体调节剂
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN104039321B (zh) * 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
EP2897948B1 (en) * 2012-09-18 2016-08-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) * 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原

Also Published As

Publication number Publication date
MX2016012103A (es) 2017-04-27
SA516371862B1 (ar) 2019-07-29
US20170096437A1 (en) 2017-04-06
DK3119396T3 (da) 2021-05-31
US20200017530A1 (en) 2020-01-16
PH12016501791A1 (en) 2017-01-09
US20220048928A1 (en) 2022-02-17
AU2015233140B2 (en) 2018-12-13
ES2872378T3 (es) 2021-11-02
JP2019112443A (ja) 2019-07-11
RU2016138788A (ru) 2018-04-23
US11034704B2 (en) 2021-06-15
RU2016138788A3 (es) 2018-09-03
CN106659719A (zh) 2017-05-10
EA031245B1 (ru) 2018-12-28
JP6880260B2 (ja) 2021-06-02
CA2942187A1 (en) 2015-09-24
JP2017507997A (ja) 2017-03-23
SG11201607458QA (en) 2016-10-28
AU2015233140A1 (en) 2016-09-22
RU2678835C2 (ru) 2019-02-04
CN110903306B (zh) 2022-09-23
WO2015140559A1 (en) 2015-09-24
EA201691853A1 (ru) 2016-12-30
IL247854B (en) 2021-01-31
MY193728A (en) 2022-10-27
CA2942187C (en) 2022-05-31
UA120928C2 (uk) 2020-03-10
GB201404922D0 (en) 2014-04-30
KR102368901B1 (ko) 2022-02-28
CN106659719B (zh) 2019-11-22
PH12016501791B1 (en) 2017-01-09
KR20160148532A (ko) 2016-12-26
HK1231382A1 (zh) 2017-12-22
AU2019201560B2 (en) 2020-09-03
IL247854A0 (en) 2016-11-30
MX2020010674A (es) 2020-10-28
AU2020280982A1 (en) 2021-01-07
CN110903306A (zh) 2020-03-24
EP3119396B1 (en) 2021-05-05
JP6498691B2 (ja) 2019-04-10
BR112016021590A2 (es) 2017-08-15
US20180327426A1 (en) 2018-11-15
US10428088B2 (en) 2019-10-01
JP2020079291A (ja) 2020-05-28
AP2016009445A0 (en) 2016-09-30
US10030035B2 (en) 2018-07-24
NZ724378A (en) 2020-12-18
EP3119396A1 (en) 2017-01-25
BR112016021590B1 (pt) 2022-07-05
AU2019201560A1 (en) 2019-03-28
JP6660502B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2018000292A1 (es) Compuestos farmacéuticos
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2017002452A1 (es) Nuevos compuestos bicíclicos
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
SV2017005381A (es) Compuestos de imidazopiridazina
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
ECSP17069696A (es) Compuestos novedosos
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
EA201692227A1 (ru) Производные сложных аминоэфиров
BR112017025901A2 (pt) composto, composição farmacêutica e uso de um composto
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists